Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999–2008)

Curtis W. Dewey Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853

Search for other papers by Curtis W. Dewey in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVIM, DACVS
,
Sofia Cerda-Gonzalez Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853

Search for other papers by Sofia Cerda-Gonzalez in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Daniel J. Fletcher Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853

Search for other papers by Daniel J. Fletcher in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVECC
,
Marcella F. Harb-Hauser Pet Emergency and Specialty Center of Marin, 901 E San Francisco Blvd, San Rafael, CA 94901

Search for other papers by Marcella F. Harb-Hauser in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Jonathan M. Levine Department of Veterinary Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843

Search for other papers by Jonathan M. Levine in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Britton L. Badgley Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853

Search for other papers by Britton L. Badgley in
Current site
Google Scholar
PubMed
Close
,
Natasha J. Olby Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606

Search for other papers by Natasha J. Olby in
Current site
Google Scholar
PubMed
Close
 VetMB, PhD, DACVIM
, and
G. Diane Shelton Department of Pathology, School of Medicine, University of California-San Diego, La Jolla, CA 92093

Search for other papers by G. Diane Shelton in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVIM

Abstract

Objective—To compare clinical outcome in dogs with serologically diagnosed acquired myasthenia gravis (MG) treated with pyridostigmine bromide (PYR) with that of dogs treated with mycophenolate mofetil (MMF) and PYR (MMF + PYR).

Design—Retrospective case series.

Animals—27 dogs.

Procedures—Medical records from August 1999 through February 2008 were reviewed to identify dogs with serologically diagnosed acquired MG treated with PYR or MMF + PYR. Data collected for each dog included signalment, whether the dog had megaesophagus or pneumonia (or both), thyroid hormone concentration, remission, time to remission, and survival time. Rates for detection of clinical signs and survival time were compared. Survival time was estimated via the Kaplan-Meier method. Influence of drug treatment protocol on likelihood of remission, time to remission, and survival time was examined. Effects of MMF treatment, megaesophagus, pneumonia, and low serum thyroid hormone concentration on time to remission and survival time were also analyzed.

Results—12 dogs were treated with PYR, and 15 were treated with MMF + PYR. Mortality rates were 33% (PYR) and 40% (MMF + PYR). There was pharmacological remission in 5 and 6 dogs in the PYR and MMF + PYR groups, respectively. No significant differences were detected between treatment groups for remission rate, time to remission, or survival time. Megaesophagus, pneumonia, and low serum thyroid hormone concentration had no significant effect on time to remission or survival time for either treatment group.

Conclusions and Clinical Relevance—The results did not support routine use of MMF for the treatment of dogs with acquired MG.

Abstract

Objective—To compare clinical outcome in dogs with serologically diagnosed acquired myasthenia gravis (MG) treated with pyridostigmine bromide (PYR) with that of dogs treated with mycophenolate mofetil (MMF) and PYR (MMF + PYR).

Design—Retrospective case series.

Animals—27 dogs.

Procedures—Medical records from August 1999 through February 2008 were reviewed to identify dogs with serologically diagnosed acquired MG treated with PYR or MMF + PYR. Data collected for each dog included signalment, whether the dog had megaesophagus or pneumonia (or both), thyroid hormone concentration, remission, time to remission, and survival time. Rates for detection of clinical signs and survival time were compared. Survival time was estimated via the Kaplan-Meier method. Influence of drug treatment protocol on likelihood of remission, time to remission, and survival time was examined. Effects of MMF treatment, megaesophagus, pneumonia, and low serum thyroid hormone concentration on time to remission and survival time were also analyzed.

Results—12 dogs were treated with PYR, and 15 were treated with MMF + PYR. Mortality rates were 33% (PYR) and 40% (MMF + PYR). There was pharmacological remission in 5 and 6 dogs in the PYR and MMF + PYR groups, respectively. No significant differences were detected between treatment groups for remission rate, time to remission, or survival time. Megaesophagus, pneumonia, and low serum thyroid hormone concentration had no significant effect on time to remission or survival time for either treatment group.

Conclusions and Clinical Relevance—The results did not support routine use of MMF for the treatment of dogs with acquired MG.

  • 1.

    Shelton GD. Treatment of autoimmune myasthenia gravis. In: Bonagura JD, Twedt DC, eds. Kirk's current veterinary therapy XIV. St Louis: Saunders, 2009;11081111.

    • Search Google Scholar
    • Export Citation
  • 2.

    Shelton GD, Schule A, Kass PH. Risk factors for acquired myasthenia gravis in dogs: 1,154 cases (1991–1995). J Am Vet Med Assoc 1997;211:14281431.

    • Search Google Scholar
    • Export Citation
  • 3.

    Shelton GD. Myasthenia gravis and disorders of neuromuscular transmission. Vet Clin North Am Small Anim Pract 2002;32:189206.

  • 4.

    Penderis J. Junctionopathies: disorders of the neuromuscular junction. In: Dewey CW, ed. A practical guide to canine and feline neurology. 2nd ed. Ames, Iowa: Wiley-Blackwell, 2008;517557.

    • Search Google Scholar
    • Export Citation
  • 5.

    Dewey CW, Bailey CS, Shelton GD, et al. Clinical forms of acquired myasthenia gravis in dogs: 25 cases (1988–1995). J Vet Intern Med 1997;11:5057.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    King LG, Vite CH. Acute fulminating myasthenia gravis in five dogs. J Am Vet Med Assoc 1998;212:830834.

  • 7.

    Shelton GD, Lindstrom JM. Spontaneous remission in canine myasthenia gravis: implications for assessing human MG therapies. Neurology 2001;57:21392141.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Maddison JE, Waelchli-Suter CM, Johnson RP. Clinical remission after corticosteroid therapy of acquired myasthenia in three dogs. J Am Vet Med Assoc 1984;184:845848.

    • Search Google Scholar
    • Export Citation
  • 9.

    Dewey CW, Coates JR, Ducoté JM, et al. Azathioprine therapy for acquired myasthenia gravis in five dogs. J Am Anim Hosp Assoc 1999;35:396402.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Bexfield NH, Watson PJ, Herrtage ME. Management of myasthenia gravis using cyclosporine in 2 dogs. J Vet Intern Med 2006;20:14871490.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Kent M. Therapeutic options for neuromuscular diseases. Vet Clin North Am Small Anim Pract 2004;34:15251551.

  • 12.

    Dewey CW, Boothe DM, Rinn KL, et al. Treatment of a myasthenic dog with mycophenolate mofetil. J Vet Emerg Crit Care 2000;10:177187.

  • 13.

    Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005;14 (suppl 1):28.

  • 14.

    Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 2006;34:284291.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Shelton GD, Cardinet GH, Lindstrom JM. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology 1988;38:14171424.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis [serial online] 2007;2:44. Available at: www.OJRD.com/content/2/1/44.

  • 17.

    Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912913.

    • Search Google Scholar
    • Export Citation
  • 18.

    Meriggioli MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000;23:12871289.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61:14381440.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Chaudry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:9496.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Ciafaloni E, Massey JM, Tucker-Lipscomb B, et al. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:9799.

  • 22.

    Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol 2008;255:510513.

  • 23.

    Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394399.

    • Search Google Scholar
    • Export Citation
  • 24.

    Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400406.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Sanders DB, Siddiqi ZA. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann N Y Acad Sci 2008;1132:249253.

  • 26.

    Benatar M, Rowland LP. The muddle of mycophenolate mofetil in myasthenia. Neurology 2008;71:390391.

  • 27.

    Phan C, Sanders DB, Siddiqi ZA. Mycophenolate mofetil in myasthenia gravis: the unanswered question. Expert Opin Pharmacother 2008;9:25452551.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement